Expert Perspectives on Nonsteroidal MRAs and Cardiorenal Protection
Muthiah Vaduganathan, MD, MPH
Anuradha Lala-Trindade, MD
Brendon Neuen, MBBS, PhD
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
Riccardo Maria Inciardi, MD, PhD
Practical Strategies for Optimizing Outcomes in Patients with Iron Deficiency and Heart Failure
Robert J. Mentz, MD, FHFSA, FACC, FAHA
Piotr Ponikowski, MD, PhD, FESC, FHFA
Latest Clinical Trial Outcomes and Breakthroughs for FCS
Daniel Gaudet, MD, PhD
Pam R. Taub, MD, FACC, FASPC
SHTG: Defining the Unmet Clinical Need
Kausik Ray, MBChB, MD, MPhil
APOC3 Inhibition: New Frontiers Managing Patients with FCS & SHTG
Børge G. Nordestgaard, MD, DMSc
SHTG: Decoding the Latest Clinical Trial Outcomes
Targeting Mixed Hyperlipidemia with APOC3 Inhibition
Remnant Cholesterol: The Missing Link in ASCVD risk
Cracking the Case: A Clinical Consult on Potassium Binders in Patients with Chronic Kidney Disease and Heart Failure
Jan T. Kielstein, MD, FASN, FERA
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
John Ostrominski
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
Jonathan Cunningham, MD
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
Akshay S. Desai, MD
NYHA FC and Finerenone Response: Clinical Trial Insights
Role of echocardiography in risk stratification and treatment decision-making
Maurizio Pieroni, MD, PhD
Tailoring Treatment for Optimal Outcomes in Patients With AAV
Bernhard Hellmich, MD
Andreas Kronbichler, MD
Loading...
We're glad to see you're enjoying PACE-CME… but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.